CX FOMO: The Medical Affairs AI Lab
An evening for medical affairs leaders to discuss, learn from peers,
and get hands-on with AI.
Wednesday, September 9th, 2026
16:00-18:30 CET
Mandarin Oriental, Zürich
The countdown has started
Days
Hours
About the Event
Medical affairs teams are sitting on some of the most valuable assets in the organization. They have the KOL relationships, the scientific credibility, the congress presence. And still, most of the engagement data never gets captured. The follow-up never happens. The insight dies in a notebook.
This evening is for medical affairs professionals who want to change that.
Co-hosted by Onomi and Shyft, it’s a working session built around a simple observation: medical is leaving a lot on the table. The tools and the ownership model haven’t caught up to the opportunity yet.
This is an invite-only event. No vendor pitches. Just peers working through a question most medical teams are sitting with right now: where does AI actually fit in our work, and where do we start?
What You Will Experience
The Potential of Medical Affairs
Presented by Philip Vyt
You have the KOL relationships, the scientific depth, the congress presence. The question is how much of it is actually working for you. Before the session, you’ll complete a short maturity assessment and at the meeting, you’ll see exactly where your peers stand and what the teams pulling ahead are doing differently.
Congress: Your Highest-leverage Move
Presented by Pierre Metrailler
Congress is where it starts. It’s the highest-density, easiest-to-measure entry point: one congress generates 40+ structured data points you can act on immediately. The same approach: “capture, structure, activate,” is what MSLs can apply to call notes and insight logs, and what regional teams can apply to KOL mapping. We’re building the sharpest version of it live, because a working example beats a slide about “AI for medical affairs.”
Peer-to-peer Exchange
Med affairs leaders from four global pharma companies
A panel of medical affairs leaders sharing honest stories: what moved the needle, what didn’t, and how they made the case internally for doing things differently.
The AI Lab: Build Your Own Agent
Led by Pierre Metrailler and Philip Vyt
Bring your laptop. We’ll build a congress follow-up agent in Copilot from scratch as a low-effort, high-value workflow your team can run the week after.
Networking Drinks
The sessions will be followed by networking drinks and nibbles with fellow pharma peers from the Zürich and Basel region.
Who Should Attend
This event is for medical affairs professionals asking where AI fits in their day-to-day work. Whether you’re thinking about MSL productivity, insights workflows, or larger initiatives at country or regional level, this session is built around that.
For global and regional medical leads: A working model for scaling AI beyond one team.
For MSL leaders: A template for turning field notes into structured insight.
For medical engagement managers and omnichannel professionals: The CRM-integrated version of all of it.
Practical Info
There is no fee for this event.
Event location: Mandarin Oriental, Poststrasse 12, 8001 Zürich (10-min walk from the train station)
Places are limited. This is an invite-only event.
Bringing You Experts in the Field
Pierre Metrailler
CEO
Onomi & SpotMe
Philip Vyt
Founder
Shyft
Panelists
To be announced
Pharma company
About Onomi
Onomi is a platform that helps pharma instrument scientific exchanges at congresses, webinars and advisory boards – connecting KOL engagement, booth insights, and symposium data into a single evidence layer integrated with your CRM.
With over 22 years of experience & trusted by 15 of the top 20 life science companies, Onomi creates engaging HCP experiences, measures real impact & is more cost-effective than traditional point solutions.
For more information, reach out today.
About Shyft
Shyft helps pharma and biotech teams close the gap between omnichannel strategy and what actually gets executed in the field. Founded by Philip Vyt, Shyft works with global and local medical and commercial teams across oncology, neurology, rheumatology, and rare disease.
